Study wrapper · #338
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Editor's note
This is a prespecified, integrated subgroup analysis of the two RECONNECT Phase 3 randomized, placebo-controlled trials — the pivotal evidence behind bremelanotide's (PT-141) FDA approval for acquired, generalized HSDD in premenopausal women. Across 1,202 patients, researchers reported statistically significant improvements in sexual desire and reductions in distress that held across age, weight, BMI and testosterone subgroups, suggesting the effect is not confined to a narrow demographic. That consistency is the analysis's real contribution. Two cautions: subgroup analyses are exploratory even when prespecified, and statistical significance is not magnitude — the parent trials' effect sizes were modest, on the order of half an additional satisfying event per month. This abstract also does not report adverse events, which elsewhere in the program were frequent (nausea, flushing). Read this as evidence that the approved effect is broadly distributed, not as evidence it is large.
Plain-language abstract
Bremelanotide (PT-141) is an FDA-approved injection for premenopausal women with a specific condition — acquired, generalized low sexual desire that causes distress (HSDD). This report re-examines data from the two large RECONNECT trials, in which 1,202 women gave themselves either bremelanotide 1.75 mg or a placebo under the skin, as needed, before sexual activity for 24 weeks. The researchers wanted to know whether the drug worked similarly in different groups of women, sorted ahead of time by age, weight, body mass index, and testosterone level. They measured changes in a desire questionnaire and a distress score. They found that bremelanotide produced statistically significant gains in desire and reductions in distress across nearly all of these subgroups, with a few exceptions, and worked whether or not women used hormonal contraception. This report focuses on who benefits rather than by how much, and does not list side effects.